Tag:
Cell Genesys
Latest Headlines
Latest Headlines
Takeda makes $8.8B bid for Millennium
Looking to expand out of a budget-bound Japanese market, Takeda is taking a big chunk of its $10 billion war chest and offering $8.8 billion in cash for U.S.-based
Cell Genesys scores $320M blockbuster deal
Japan's Takeda Pharmaceutical  will pay Cell Genesys $50 million upfront and up to $270 million more for hitting
C&L: Stonehouse tapped to run Biocryst
BioCryst Pharmaceuticals announced that Jon P. Stonehouse, has been appointed CEO and a member of the company's board of directors. Stonehouse succeeds Charles E. Bugg, Ph.D., founder and former CEO who previously announced his intention to retire in 2007. In his new role, Dr. Bugg will become non-executive chairman of …
C&L: Cell Genesys COO Vallner resigns
Cell Genesys announced that Joseph J. Vallner, Ph.D., the company's president and COO, has resigned to become the CFO of an early-stage, private biotechnology company. Le@p Technology has named Dr. Donald J. Ciappenelli as CEO and chairman. Access Genetics has named industry veteran …
Blair touts biotech biz in San Francisco sit-down
Singling out Genentech for high praise, British Prime Minister Tony Blair sat down with a group of biotech execs in San Francisco yesterday to highlight his own commitment to boosting Britain's drug development industry. In a marked break with the Bush administration, Blair also emphasized the need for more research work in embryonic stem cells. A number of British biotech officials feel their country's research groups have stolen a march on the U.S., pushing ahead while stem cell work in …
ALSO NOTED: Cadence files $86.3M IPO; Chutes & Ladders: Merck exec steps down; and much more...
> Yesterday, Cadence Pharmaceuticals filed an $86.3 million IPO with the SEC. The company currently has two Phase III products in development. Release > Cangene today has filed an NDA for its recombinant human growth hormone product (rhGH) Accretropin with the FDA. Accretropin combats short stature in children with growth hormone deficiency and girls with Turner Syndrome. …
ALSO NOTED: Nektar gains fast track for lung infection drug; Vertex reports positive hep C data; and much more...
> Nektar Therapeutics was given a fast-track designation for its lung infection prevention drug. Report > Vertex announced that all 12 patients in a mid-stage trial of its VX-950 hepatitis C therapy showed no detectable signs of the virus after 28 days of therapy. Report > ViroPharma announced …
SPOTLIGHT: Cancer vaccines make headway
US News & World Report reports on the development of new cancer vaccines, with a special focus on Cell Genesys. Cell Genesys recently arranged $75 million in new capital. Article
ALSO NOTED: Cell Genesys arranges financing; GenVec expands TNFerade trial; Wisconsin to build flu research center;and much mor
> Cell Genesys of South San Francisco has arranged $75 million in financing from Kingsbridge Capital over the next three years. Report > The FDA has given GenVec approval to expand a mid-stage trial of TNFerade for pancreatic cancer into a Phase II/III study. GenVec also announced that Kingsbridge Capital will provide $30 million in financing over three years. …
ALSO NOTED: Varian buys IonSpec; China's Phynova debuts;and much more...
> Varian acquired IonSpec for $16 million. Varian gains the Fourier Transform mass spectrometry technology for its information-rich detection portfolio. Report > China's Phynova surged on its public debut today. The drug developer has six drug candidates in the pipeline. Report > Cell Genesys says that …
